Table III.
Association of CLDN6 expression level with clinical and pathological features of gastric cancer patients.
| Clinical and pathological features | n=213 | CLDN6 (ng/ml) | t (statistical value) | P-value (statistical difference) |
|---|---|---|---|---|
| Sex | 0.663 | |||
| Male | 115 | 1.35±0.18 | 0.436 | |
| Female | 98 | 1.34±0.15 | ||
| Age (years) | <0.001 | |||
| ≤50 | 86 | 1.42±0.17 | 4.672 | |
| >50 | 127 | 1.28±0.24 | ||
| Lymph node metastasis | <0.001 | |||
| Yes | 154 | 1.27±0.21 | 4.629 | |
| No | 59 | 1.41±0.16 | ||
| Pathological staging | <0.001 | |||
| Stage I–II | 75 | 1.39±0.11 | 4.939 | |
| Stage III–IV | 138 | 1.24±0.25 | ||
| Distant metastasis | <0.001 | |||
| Yes | 132 | 1.25±0.22 | 5.420 | |
| No | 81 | 1.41±0.19 | ||
| Location classification of the disease | 0.461 | |||
| Gastric fundus and cardia cancer | 95 | 1.31±0.22 | 0.777 | |
| Gastric corpus cancer | 65 | 1.23±0.31 | ||
| Gastric antrum cancer | 53 | 1.26±0.18 |
CLDN6, claudin-6.